The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study

被引：25

作者：

Nozaki, Akito ^{[1
]}

Atsukawa, Masanori ^{[2
]}

Kondo, Chisa ^{[2
]}

Toyoda, Hidenori ^{[3
]}

Chuma, Makoto ^{[1
]}

Nakamuta, Makoto ^{[4
]}

Uojima, Haruki ^{[5
]}

Takaguchi, Koichi ^{[6
]}

Ikeda, Hiroki ^{[7
]}

Watanabe, Tsunamasa ^{[7
]}

Ogawa, Shintaro ^{[8
,9
]}

Itokawa, Norio ^{[10
]}

Arai, Taeang ^{[11
]}

Hiraoka, Atsushi ^{[12
]}

Asano, Toru ^{[13
]}

Fujioka, Shinichi ^{[14
]}

Ikegami, Tadashi ^{[15
]}

Shima, Toshihide ^{[16
]}

Ogawa, Chikara ^{[17
]}

Akahane, Takehiro ^{[18
]}

Shimada, Noritomo ^{[19
]}

Fukunishi, Shinya ^{[20
]}

Abe, Hiroshi ^{[21
]}

Tsubota, Akihito ^{[22
]}

Genda, Takuya ^{[23
]}

Okubo, Hironao ^{[24
]}

Mikami, Shigeru ^{[25
]}

Morishita, Asahiro ^{[26
]}

Moriya, Akio ^{[27
]}

Tani, Joji ^{[28
]}

Tachi, Yoshihiko ^{[29
]}

Hotta, Naoki ^{[30
]}

Ishikawa, Toru ^{[31
]}

Okanoue, Takeshi ^{[16
]}

Tanaka, Yasuhito ^{[8
,9
]}

Kumada, Takashi ^{[3
]}

Iwakiri, Katsuhiko ^{[2
]}

Maeda, Shin ^{[1
,32
]}

机构：

[1] Yokohama City Univ, Med Ctr, Gastroenterol Ctr, Minami Ku, 4-57 Urafune Cho, Yokohama, Kanagawa 2320024, Japan

[2] Nippon Med Sch, Div Gastroenterol & Hepatol, Dept Internal Med, Tokyo, Japan

[3] Ogaki Municipal Hosp, Dept Gastroenterol, Ogaki, Japan

[4] Natl Hosp Org Kyushu Med Ctr, Fukuoka, Japan

[5] Kitasato Univ, Sch Med, Dept Gastroenterol, Internal Med, Sagamihara, Kanagawa, Japan

[6] Kagawa Prefectural Cent Hosp, Dept Hepatol, Takamatsu, Kagawa, Japan

[7] St Marianna Univ, Sch Med, Dept Internal Med, Kawasaki, Kanagawa, Japan

[8] Nagoya City Univ, Grad Sch Med Sci, Dept Virol, Nagoya, Aichi, Japan

[9] Nagoya City Univ, Grad Sch Med Sci, Liver Unit, Nagoya, Aichi, Japan

[10] Chiba Hokusoh Hosp, Nippon Med Sch, Dept Internal Med, Div Gastroenterol, Inzai, Japan

[11] Musashikosugi Hosp, Nippon Med Sch, Dept Internal Med, Div Gastroenterol, Kawasaki, Kanagawa, Japan

[12] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, Matsuyama, Ehime, Japan

[13] Tokyo Metropolitan Bokutoh Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo, Japan

[14] Okayama Saiseikai Gen Hosp, Dept Gastroenterol, Okayama, Japan

[15] Tokyo Med Univ, Ibaraki Med Ctr, Ibaraki, Japan

[16] Saiseikai Suita Hosp, Dept Gastroenterol & Hepatol, Suita, Osaka, Japan

[17] Takamatsu Red Cross Hosp, Dept Gastroenterol & Hepatol, Takamatsu, Kagawa, Japan

[18] Japanese Red Cross Ishinomaki Hosp, Dept Gastroenterol, Ishinomaki, Japan

[19] Otakanomori Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Kashiwa, Chiba, Japan

[20] Osaka Med Coll, Dept Internal Med 2, Osaka, Japan

[21] Shinmatsudo Cent Gen Hosp, Div Gastroenterol & Hepatol, Dept Internal Med, Matsudo, Chiba, Japan

[22] Jikei Univ, Sch Med, Core Res Facil Basic Sci, Tokyo, Japan

[23] Juntendo Shizuoka Univ Hosp, Dept Gastroenterol, Shizuoka, Japan

[24] Juntendo Nerima Univ Hosp, Dept Gastroenterol, Tokyo, Japan

[25] Kikkoman Gen Hosp, Dept Internal Med, Div Gastroenterol, Noda, Chiba, Japan

[26] Kagawa Univ, Dept Gastroenterol, Grad Sch Med, Takamatsu, Kagawa, Japan

[27] Mitoyo Gen Hosp, Dept Gastroenterol, Kannonji, Japan

[28] Yashima Gen Hosp, Dept Internal Med, Takamatsu, Kagawa, Japan

[29] Fujita Hlth Univ, Bantane Hosp, Sch Med, Nagoya, Aichi, Japan

[30] Masuko Mem Hosp, Dept Internal Med, Div Hepatol, Nagoya, Aichi, Japan

[31] Saiseikai Niigata Daini Hosp, Dept Hepatol, Niigata, Japan

[32] Yokohama City Univ, Grad Sch Med, Dept Gastroenterol, Yokohama, Kanagawa, Japan

来源：

HEPATOLOGY INTERNATIONAL | 2020年 / 14卷 / 02期

基金：

日本学术振兴会;

关键词：

Glecaprevir; Pibrentasvir; Chronic hepatitis C; Refractory factors; Multicenter study; GENOTYPE; 2; INFECTED PATIENTS; JAPANESE PATIENTS; HCV; PIBRENTASVIR; GLECAPREVIR; EFFICACY; SOFOSBUVIR; RATES;

D O I：

10.1007/s12072-020-10019-z

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background Direct-acting anti-virals (DAAs) have markedly improved the effectiveness of anti-viral therapy for chronic hepatitis C (CHC) patients. In a phase III trial in Japan, treatment with the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir (G/P) resulted in a small number of patients with refractory factors. We aimed to evaluate the effectiveness and safety of G/P, especially among patients with these refractory factors, and the influence of these factors on treatment. Methods In a prospective, multicenter study involving 33 medical institutions, 1439 patients were treated with G/P, and their efficacy, safety, and most frequent adverse effects (AEs) were analyzed. Results Overall SVR12 rates were 99.1% (1397/1410) in the per-protocol-analysis, and genotype sustained virologic response SVR12 rates were: genotype 1, 99.4% (707/711); genotype 2, 99.4% (670/674); genotype 3, 80.0% (16/20). DAA-naive patients (p = 0.008) with HCV genotype except 3 (genotype 1 vs. 3, p = 2.68 x 10(-5); genotype 2 vs. 3, p = 3.28 x 10(-5)) had significantly higher SVR12 rates. No significant difference was observed between CKD stage 1-3 (99.1% [1209/1220]) and chronic kidney disease (CKD) stage 4-5 (98.9% [188/190]) patients, or between cirrhotic (99.0% [398/402]) and non-cirrhotic (99.1% [999/1008]) patients. Multiple logistic regression analysis revealed that genotype 3 [OR 33.404, 95% CI (7.512-148.550), p value (p = 4.06 x 10(-5))] and past experience of IFN-free DAAs [OR 3.977, 95% CI (1.153-13.725), p value (p = 0.029)] were both significantly independent predictors of non-SVR12. AEs were reported in 28.2% of patients, and 1.6% discontinued treatment owing to drug-related AEs. AEs were significantly higher in CKD stage 4-5 (41.6% [79/190]) than CKD stage 1-3 (26.1% [319/1220]) patients (p = 2.00 x 10(-5)). AEs were also significantly higher in cirrhotic (38.6% [155/402]) than in non-cirrhotic (24.1% [243/1008]) (p = 2.91 x 10(-18)) patients. Conclusions G/P regimen is highly effective and safe to treat CHC patients even with refractory factors such as CKD and advanced liver fibrosis. However, patients with past experience of IFN-free DAA treatment and genotype 3, CKD stage 4 or 5, and advanced liver fibrosis should be more closely observed.

引用

页码：225 / 238

页数：14

共 42 条

[21] Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China [J].

Lu, Jie ;

Feng, Yupeng ;

Chen, Lichang ;

Zeng, Zhengyu ;

Liu, Xianliang ;

Cai, Wei ;

Wang, Hui ;

Guo, Xiaolei ;

Zhou, Huijuan ;

Tao, Wanyin ;

Xie, Qing .

FRONTIERS IN MICROBIOLOGY, 2019, 10

[22] Revised Equations for Estimated GFR From Serum Creatinine in Japan [J].

Matsuo, Seiichi ;

Imai, Enyu ;

Horio, Masaru ;

Yasuda, Yoshinari ;

Tomita, Kimio ;

Nitta, Kosaku ;

Yamagata, Kunihiro ;

Tomino, Yasuhiko ;

Yokoyama, Hitoshi ;

Hishida, Akira .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (06) :982-992

[23] All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study [J].

Nelson, David R. ;

Cooper, James N. ;

Lalezari, Jacob P. ;

Lawitz, Eric ;

Pockros, Paul J. ;

Gitlin, Norman ;

Freilich, Bradley F. ;

Younes, Ziad H. ;

Harlan, William ;

Ghalib, Reetn ;

Oguchi, Godson ;

Thuluvath, Paul J. ;

Ortiz-Lasanta, Grisell ;

Rabinovitz, Mordechai. ;

Berastein, David ;

Bennett, Michael ;

Hawkins, Trevor ;

Ravendhran, Natarajan ;

Sheikh, Aasim M. ;

Varunok, Peter ;

Kowdley, Kris V. ;

Hennicken, Delphine ;

McPhee, Fiona ;

Rana, Ithurram ;

Hughes, Eric A. .

HEPATOLOGY, 2015, 61 (04) :1127-1135

[24]

Ng TI, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/aac.02558-16, 10.1128/AAC.02558-16]

[25] Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study [J].

Ogawa, Eiichi ;

Furusyo, Norihiro ;

Nakamuta, Makoto ;

Nomura, Hideyuki ;

Satoh, Takeaki ;

Takahashi, Kazuhiro ;

Koyanagi, Toshimasa ;

Kajiwara, Eiji ;

Dohmen, Kazufumi ;

Kawano, Akira ;

Ooho, Aritsune ;

Azuma, Koichi ;

Kato, Masaki ;

Shimoda, Shinji ;

Hayashi, Jun .

HEPATOLOGY RESEARCH, 2019, 49 (06) :617-626

[26] New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a [J].

Ohno, T ;

Mizokami, M ;

Wu, RR ;

Saleh, MG ;

Ohba, K ;

Orito, E ;

Mukaide, M ;

Williams, R ;

Lau, JYN .

JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (01) :201-207

[27] Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection [J].

Pearlman, Brian ;

Perrys, Michael ;

Hinds, Andrew .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 (09) :1550-1552

[28] Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure [J].

Poordad, Fred ;

Pol, Stanislas ;

Asatryan, Armen ;

Buti, Maria ;

Shaw, David ;

Hezode, Christophe ;

Felizarta, Franco ;

Reindollar, Robert W. ;

Gordon, Stuart C. ;

Pianko, Stephen ;

Fried, Michael W. ;

Bernstein, David E. ;

Gallant, Joel ;

Lin, Chih-Wei ;

Lei, Yang ;

Ng, Teresa I. ;

Krishnan, Preethi ;

Kopecky-Bromberg, Sarah ;

Kort, Jens ;

Mensa, Federico J. .

HEPATOLOGY, 2018, 67 (04) :1253-1260

[29] Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections [J].

Sezaki, Hitomi ;

Suzuki, Fumitaka ;

Hosaka, Tetsuya ;

Fujiyama, Shunichirou ;

Kawamura, Yusuke ;

Akuta, Norio ;

Kobayashi, Masahiro ;

Suzuki, Yoshiyuki ;

Saitoh, Satoshi ;

Arase, Yasuji ;

Ikeda, Kenji ;

Kobayashi, Mariko ;

Kumada, Hiromitsu .

JOURNAL OF GASTROENTEROLOGY, 2019, 54 (10) :916-927

[30] Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors [J].

Smith, David ;

Magri, Andrea ;

Bonsall, David ;

Ip, Camilla L. C. ;

Trebes, Amy ;

Brown, Anthony ;

Piazza, Palo ;

Bowden, Rory ;

Dung Nguyen ;

Ansari, M. Azim ;

Simmonds, Peter ;

Barnes, Eleanor .

HEPATOLOGY, 2019, 69 (05) :1861-1872

← 1 2 3 4 5 →